Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci

被引:16
作者
Lacy, MK
Tessier, PR
Nicolau, DP
Nightingale, CH
Quintiliani, R
机构
[1] Univ Kansas, Med Ctr, Sch Pharm, Dept Pharm, Kansas City, KS 66160 USA
[2] Hartford Hosp, Dept Pharm Res, Hartford, CT 06102 USA
[3] Hartford Hosp, Res Off, Hartford, CT 06102 USA
[4] Hartford Hosp, Div Infect Dis, Hartford, CT 06102 USA
关键词
vancomycin; pharmacodynamics; bactericidal; methicillin-resistant Staphylococcus aureus; coagulase-negative staphylococci; methicillin-resistant Staphylococcus epidermidis;
D O I
10.1016/S0924-8579(00)00121-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study compared the duration of serum bactericidal activity for vancomycin, 1 g every 12 or 24 h at steady state, against methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci (MR-CNS). All four test isolates were susceptible to vancomycin with minimal inhibitory concentration (MIC) values of either 2 or 4 mg/l. Serum bactericidal titres (SBTs) were run in duplicate and serum bactericidal activity (SBA) was defined as the time points at which all subject SBTs were greater than or equal to 1:2. For the every 12-h regimen, SEA was 10-12 h. With the every 24-h regimen, the duration of SEA was 10-16 h for MRSA and 8-10 h for MR-CNS. The pharmacodynamic data suggest that for those with good renal function a Q12h dosing interval is most appropriate for MR-CNS or staphylococcal isolates with MICs of 4. (C) 2000 Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 27 条
[1]   ANALYSIS OF VANCOMYCIN TIME-KILL STUDIES WITH STAPHYLOCOCCUS SPECIES BY USING A CURVE STRIPPING PROGRAM TO DESCRIBE THE RELATIONSHIP BETWEEN CONCENTRATION AND PHARMACODYNAMIC RESPONSE [J].
ACKERMAN, BH ;
VANNIER, AM ;
EUDY, EB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (08) :1766-1769
[2]  
BUNDTZEN RW, 1981, REV INFECT DIS, V3, P28
[3]   INVITRO COMPARISON OF THE POSTANTIBIOTIC EFFECT OF VANCOMYCIN AND TEICOPLANIN [J].
COOPER, MA ;
JIN, YF ;
ASHBY, JP ;
ANDREWS, JM ;
WISE, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (02) :203-207
[4]   Pharmacokinetics and pharmacodynamics of antibiotics in otitis media [J].
Craig, WA ;
Andes, D .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1996, 15 (03) :255-259
[5]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96
[6]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[7]   EFFICACIES OF DIFFERENT VANCOMYCIN DOSING REGIMENS AGAINST STAPHYLOCOCCUS-AUREUS DETERMINED WITH A DYNAMIC IN-VITRO MODEL [J].
DUFFULL, SB ;
BEGG, EJ ;
CHAMBERS, ST ;
BARCLAY, ML .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) :2480-2482
[8]  
EBERT SC, 1990, INFECT CONT HOSP EP, V11, P319
[9]  
EDWARDS DJ, 1987, CLIN PHARMACY, V6, P652
[10]  
FEKETY R, 1995, MANDELL DOUGLAS BENN, V1, P346